Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants - Takeaways - MDSpire

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants

  • By

  • Nicholas A. Marston

  • Shinwan Kany

  • Giorgio E. M. Melloni

  • Sean J. Jurgens

  • Frederick K. Kamanu

  • Yi-Pin Lai

  • Joel T. Rämö

  • Itamar Raz

  • Stephen D. Wiviott

  • Patrick T. Ellinor

  • Marc S. Sabatine

  • Christian T. Ruff

  • June 8, 2026

  • 0 min

Share

  • 1

    SGLT2 inhibitors like dapagliflozin can reduce hospitalization for heart failure across various left ventricular ejection fraction levels.

  • 2

    In the DECLARE-TIMI 58 trial, dapagliflozin significantly lowered the incidence of heart failure hospitalization in patients with type 2 diabetes.

  • 3

    Carriers of cardiomyopathy-associated genetic variants have an increased risk of heart failure hospitalization compared to noncarriers.

  • 4

    Dapagliflozin treatment resulted in an 82% reduction in heart failure hospitalization among carriers of cardiomyopathy variants.

  • 5

    The absolute risk reduction for heart failure hospitalization was significantly greater in carriers of cardiomyopathy variants compared to noncarriers.

Original Source(s)

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants

  • by Nicholas A. Marston, Shinwan Kany, Giorgio E. M. Melloni, Sean J. Jurgens, Frederick K. Kamanu, Yi-Pin Lai, Joel T. Rämö, Itamar Raz, Stephen D. Wiviott, Patrick T. Ellinor, Marc S. Sabatine, Christian T. Ruff

  • June 8, 2026

Related Content

ChatGPT response consistency to the 2025 ESC/EACTS guidelines for the management of valvular heart disease: A test–retest study using binary and multiple-choice questions

Cardiac magnetic resonance biomarkers for cardiovascular complications in diabetes: a systematic review and meta-analysis

Independent prognostic value of the triglyceride–glucose index and its incremental predictive contribution beyond traditional risk markers in acute heart failure: a retrospective cohort study